Anti-huLRRC15 antibody drug conjugates and methods for their use

Abstract

The present disclosure provides antibodies, antibody binding fragments, and antibody drug conjugates that bind human LRRC15, their methods of making, and their uses to treat patients having cancer.

What is claimed is: 
     
       1. An anti-huLRRC15 antibody drug conjugate (“ADC”) comprising an antimitotic agent linked to an anti-huLRRC15 antibody by way of a linker, wherein the ADC has a structure of formula (IIIa):
 (IIIa) 
 
       
         
           
           
               
               
           
         
         
           wherein 
         
         n is an integer ranging from 2 to 8; and 
         Ab is the anti-huLRRC15 antibody comprising
 a V H  chain comprising the sequence of SEQ ID NO:16; and 
 a V L  chain comprising the sequence of SEQ ID NO: 17. 
 
       
     
     
       2. The ADC of  claim 1  in which n is 2, 3 or 4. 
     
     
       3. The ADC of  claim 1 , wherein the anti-huLRRC15 antibody comprises
 a heavy chain comprising the sequence of SEQ ID NO:18; and 
 a light chain comprising the sequence of SEQ ID NO: 19. 
 
     
     
       4. A pharmaceutical composition comprising the ADC of  claim 1  and a pharmaceutically acceptable carrier. 
     
     
       5. A pharmaceutical composition comprising the ADC of  claim 2  and a pharmaceutically acceptable carrier. 
     
     
       6. A pharmaceutical composition comprising the ADC of  claim 3  and a pharmaceutically acceptable carrier.